Mavatar, a global specialist in AI- and data-driven precision medicine solutions, today announces the start of a non-clinical research collaboration with Sobi, a global biopharmaceutical company focused on rare diseases.
The collaboration will explore interferon gamma (IFNγ)-associated biological pathways using Mavatar’s large-scale analysis platform, Mavatar Discovery, which integrates and contextualizes publicly available transcriptomic datasets.
The research aims to generate structured, data-driven insights that can support scientific understanding in selected disease areas.
“We are pleased to collaborate with Sobi, whose deep commitment to rare diseases aligns strongly with our mission,” said Johan Juhlin, CEO and Co-founder of Mavatar.
“Through advanced analytics of public transcriptomic data, we aim to contribute to a clearer understanding of IFNγ-driven mechanisms across relevant biological contexts.”
By leveraging Mavatar’s analytical frameworks, the project will investigate IFNγ-related molecular patterns across selected datasets, supporting broader scientific exploration in immune-mediated and rare disease research.
“Understanding the underlying biology of rare and immune-mediated conditions is essential for advancing research in the field,” said Emmanuel Monet, Head Medical Science Strategy, Sobi.
“Through this collaboration, we aim to further strengthen our scientific knowledge base using structured, data-driven analyses.”
This collaboration strengthens Mavatar’s expanding work within rare disease and immunology - areas where AI- and data-driven research can help accelerate insight generation.
